Lisa M. DeAngelis

Lisa M. DeAngelis

Auto-generated profile, based on publicly available information

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center 8 Department of Neurology New York, New York

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2013 in JAMA
Verified
Journal Article
Closed access
PDF file
AOAntonio Omuro
Antonio Omuro
LDLisa M. DeAngelis
Lisa M. DeAngelis
Review from JAMA — Glioblastoma and Other Malignant Gliomas — A Clinical Review

11 January 2001 in New England Journal of Medicine
Verified
Journal Article
Closed access
LDLisa M. DeAngelis
Lisa M. DeAngelis
The term “brain tumor” refers to a collection of neoplasms, each with its own biology, prognosis, and treatment; these tumors are better identified as “intracranial neoplasms,” since some do not arise from brain tissue (e.g., meningiomas and lymphomas) (Table 1). However, for most intracranial tumors, the clinical presentation, diagnostic approach, and initial treatment are similar. This article will focus on general presentation, diagnosis, and specific treatment.EpidemiologyThe American Cancer Society estimates that 16,800 new intracranial tumors were diagnosed in 1999, more than double the number of diagnosed cases of Hodgkin's disease and over half the number of cases of . . .

1 August 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LALauren E. Abrey
Lauren E. Abrey
TBTracy T. Batchelor
Tracy T. Batchelor
AFAndrés J.M. Ferreri
Andrés J.M. Ferreri
MGMary Gospodarowicz
Mary Gospodarowicz
EPElisa J. Pulczynski
Elisa J. Pulczynski
FCFranco Cavalli
Franco Cavalli
Standardized guidelines for the baseline evaluation and response assessment of primary CNS lymphoma (PCNSL) are critical to ensure comparability among clinical trials for newly diagnosed patients. The relative rarity of this tumor precludes rapid completion of large-scale phase III trials and, therefore, our reliance on the results of well-designed phase II trials is critical. To formulate this recommendation, an international group of experts representing hematologic oncology, medical oncology, neuro-oncology, neurology, radiation oncology, neurosurgery, and ophthalmology met to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy. The response guidelines were based on the results of neuroimaging, corticosteroid use, ophthalmologic examination, and CSF cytology. A critical issue that requires additional study is the optimal method to assess the neurocognitive impact of therapy and address the quality of life of PCNSL survivors. We hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow us to develop better therapies for patients.

1 August 2017 in JACC
Verified
Journal Article
Closed access
BNBabak B. Navi
Babak B. Navi
ARAnne S. Reiner
Anne S. Reiner
HKHooman Kamel
Hooman Kamel
CICostantino Iadecola
Costantino Iadecola
POPeter M. Okin
Peter M. Okin
LDLisa M. DeAngelis
Lisa M. DeAngelis

15 December 2002 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LDLisa M. DeAngelis
Lisa M. DeAngelis
WSWendy Seiferheld
Wendy Seiferheld
SSS. Clifford Schold
S. Clifford Schold
BFBarbara Fisher
Barbara Fisher
CSChristopher J. Schultz
Christopher J. Schultz
PURPOSE: Primary CNS lymphoma (PCNSL) is an aggressive primary brain tumor. Cranial irradiation alone rarely results in long-term disease control or prolonged survival. We prospectively studied the use of combination chemotherapy plus cranial irradiation in newly diagnosed patients with PCNSL. PATIENTS AND METHODS: We enrolled 102 newly diagnosed, immunocompetent patients with PCNSL; 98 were assessable. Patients first received five cycles of methotrexate 2.5 g/m2, vincristine, procarbazine, and intraventricular methotrexate (12 mg). Whole-brain radiotherapy (RT) was administered to a total dose of 45 Gy and all patients received high-dose cytarabine after RT. RESULTS: Fifty-eight percent of patients with measurable disease had a complete response to preirradiation chemotherapy and 36% had a partial (> 50%) response, for a 94% response rate. Median progression-free survival was 24.0 months and overall survival was 36.9 months. Age was an important prognostic factor; median survival was 50.4 months in patients younger than 60 and only 21.8 months in those aged 60 or older (P < .001). Fifty-three percent of patients had grade 3 or 4 toxicity during induction chemotherapy, half of which was hematologic. However, 12 patients (15%) experienced severe delayed neurologic toxicity, eight of whom died. CONCLUSION: This is the first multicenter trial demonstrating improved survival with the combination of chemotherapy plus RT compared with previous reports of RT alone. A high-dose methotrexate-based regimen produced a high response rate before RT was administered. High-dose methotrexate combined with cranial irradiation is an effective therapeutic approach to PCNSL, but neurotoxicity is a delayed risk of this approach.

20 July 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CGChristian Grommes
Christian Grommes
LDLisa M. DeAngelis
Lisa M. DeAngelis
Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic spread. The prognosis of patients with PCNSL has improved during the last decades with the introduction of high-dose methotrexate. However, despite recent progress, results after treatment are durable in half of patients, and therapy can be associated with late neurotoxicity. PCNSL is an uncommon tumor, and only four randomized trials and one phase III trial have been completed so far, all in the first-line setting. To our knowledge, no randomized trial has been conducted for recurrent/refractory disease, leaving many questions unanswered about optimal first-line and salvage treatments. This review will give an overview of the presentation, evaluation, and treatment of immunocompetent patients with PCNSL.